Oral contraceptives for functional ovarian cysts

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Grimes, David A ^a   Jones, L B ^b   Lopez, L M ^b   Schulz, K F ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; MESTRANOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DATA EXTRACTION; EMBASE; ENDOMETRIUM TUMOR; FERTILITY; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; OVARY CYST; OVULATION INDUCTION; PATHOLOGY; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL; REFERENCE DATABASE; REVIEW; RISK; SYSTEMATIC REVIEW;

EID: 34548144934     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006134.pub2     Document Type: Review

References (36)

1. Ben-Ami M, Geslevich Y, Battino S, Matilsky M, Shalev E. Management of functional ovarian cysts after induction of ovulation. A randomized prospective study. Acta Obstetricia Gynecologica Scandinavica 1993;72:396-7.
2. Steinkampf MP, Hammond KR, Blackwell RE. Hormonal treatment of functional ovarian cysts: a randomized, prospective study. Fertility and Sterility 1990;54:775-7.
3. Taskin O, Young DC, Mangal R, Aruh I. Prevention and treatment of ovarian cysts with oral contraceptives: a prospective randomized study. Journal of Gynecologic Surgery 1996;12:21-4.
4. Turan C, Zorlu CG, Ugur M, Ozcan T, Kaleli B, Gokmen O. Expectant management of functional ovarian cysts: an alternative to hormonal therapy. International Journal of Gynecology and Obstetrics 1994;47:257-60.
5. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. Journal of Assisted Reproduction and Genetics 1998;15:599-604.
6. Egarter C, Putz M, Strohmer H, Speiser P, Wenzl R, Huber J. Ovarian function during low-dose oral contraceptive use. Contraception 1995;51:329-33.
7. Graf M, Krussel JS, Conrad M, Bielfeld P, Rudolf K. Regression of functional cysts: high dosage ovulation inhibitor and gestagen therapy has no added effect [Zur Ruckbildung funktioneller Zysten: Hochdosierte Ovulationshemmer und Gestagentherapie ohne zusatzlichen Effekt]. Geburtshilfe und Frauenheilkunde 1995;55:387-92.
8. Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstetrics and Gynecology 1994;83:29-34.
9. MacKenna A, Fabres C, Alam V,Morales V. Clinical management of functional ovarian cysts: a prospective and randomized study. Human Reproduction 2000;15:2567-9.
10. Muzii L, Marana R, Caruana P, Catalano GF, Margutti, Panici PB. Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. American Journal of Obstetrics and Gynecology 2000;183:588- 92.
11. Nezhat F, Nezhat CH, Borhan S, Nezhat CR. Is hormonal suppression efficacious in treating functional ovarian cysts?. Journal of the American Association of Gynecologic Laparoscopists 1994;1:S26.
12. Nezhat CH, Nezhat F, Borhan S, Seidman DS, Nezhat CR. Is hormonal treatment efficacious in the management of ovarian cysts in women with histories of endometriosis?. Human Reproduction 1996;11:874-7.
13. Peres JAT, Baracat EC, Novo NF, Juliano Y, de Lima GR. Behavior of cystic tumor of the ovary after wait-and-see management and hormonal treatment [Comportamento dos tumores cisticos do ovario apos conduta expectante e tratamento hormonal]. Revista Paulista de Medicina 1991;109:165- 73.
14. Teichmann AT, Brill K, Albring M, Schnitker J, Wojtynek P, Kustra E. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. Gynecological Endocrinology 1995;9:299-305.
15. Young RL, Snabes MC, Frank ML, Reilly M. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. American Journal of Obstetrics and Gynecology 1992;167:678-82.
16. Anderson RE, Serafini PC, Paulson RJ, Sauer MV, Marrs RP. Detection and management of pathological, non-palpable, cystic adnexal masses. Human Reproduction 1990;5:279-81.
17. Anonymous. Functional ovarian cysts and oral contraceptives. Negative association confirmed surgically. A cooperative study. Journal of the American Medical Association 1974;228:68-9.
18. Anonymous. Should OCs be prescribed to prevent adnexal masses?. Contraceptive Technology Update 1982;3:116-8.
19. Anonymous. Retraction. Surgical Laparoscopy Endoscopy and Percutaneous Techniques 2001;11:1.
20. Booth M, Beral V, Maconochie N, Carpenter L, Scott C. A case-control study of benign ovarian tumors. Journal of Epidemiology and Community Health 1992;46:528-31.
21. Carlson W, Russell S. Journal retracts Stanford doctors' research articles. Co-author admits using inaccurate data on women's surgeries in report. San Francisco Chronicle, February 21 2001.
22. Chiaffarino F, Parazzini F, LaVecchia C, Ricci E, Crosignani PG. Oral contraceptive use and benign gynecologic conditions. Contraception 1998;57:11-8.
23. Christensen J, Boldsen J, Westergaard J. Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception 2002;66:153-7.
24. The ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Human Reproduction 2001;16:1527-35.
25. Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstetrics and Gynecology 1992;79:529-33.
26. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital and Health Statistics 2005;13 (158):1-207.
27. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. American Journal of Obstetrics and Gynecology 1992;166:956-61.
28. Muram D, Gale CL, Thompson E. Functional ovarian cysts in patients cured of ovarian neoplasms. Obstetrics and Gynecology 1990;75:680-3.
29. Parazzini F, Moroni S, Negri E, La Vecchia C, Dal Pino D, Ricci E. Risk factors for functional ovarian cysts. Epidemiology 1996;7:547-9.
30. Spanos WJ. Preoperative hormonal therapy of cystic adnexal masses. American Journal of Obstetrics and Gynecology 1973;116:551-6.
31. Starks GC. Therapeutic uses of contraceptive steroids. Journal of Family Practice 1984;19:315-21.
32. Stein AL, Koonings PP, Schlaerth JB, Grimes DA, d'Ablaing G 3d. Relative frequency of malignant parovarian tumors: should parovarian tumors be aspirated?. Obstetrics and Gynecology 1990;75:1029-31.
33. Teichmann AT, Brill K, Albring M, Schnitker J, Wojtynek P, Kustra E. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. Gynecological Endocrinology 1995;9:299-305.
34. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. British Medical Journal 1987;294:1518-20.
35. Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives, vol. 3. Bethesda, MD: National Institutes of Health, 1981.
36. Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and in the United States. British Journal of Obstetrics and Gynaecology 1992;99:329-32.